<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176291</url>
  </required_header>
  <id_info>
    <org_study_id>PRO13120236</org_study_id>
    <secondary_id>R34MH101371</secondary_id>
    <nct_id>NCT02176291</nct_id>
  </id_info>
  <brief_title>Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine</brief_title>
  <acronym>IRLGREY-B</acronym>
  <official_title>Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jordan F. Karp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this project are to examine the feasibility, safety, tolerability and
      clinical effect of low-dose buprenorphine as a novel treatment for late-life
      treatment-resistant depression and to develop preliminary data about mechanism of action.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to one half of older patients with major depression develop Late-Life Treatment Resistant
      Depression (LL-TRD). Consequences of LL-TRD include suicide, worsened medical conditions,
      increased caregiver burden, and higher all-cause mortality. The development and testing of
      novel-mechanism pharmacotherapies is a public health priority embraced by National Institute
      of Mental Health (NIMH). Among the neuropeptidergic transmitters, opioids are known to
      modulate mood, and this system is often altered in patients with major depression. Targeting
      the opiate system in LL-TRD may positively modulate a system in which there is age-associated
      imbalance between circulating opiates and the density and binding affinity of mu and kappa
      opiate receptors. Buprenorphine (BPN) is an antagonist at the kappa opiate receptor and a
      partial agonist at the mu opiate receptor. Either, or both, of these pharmacodynamic actions
      may underlie its putative antidepressant effects. Our research group has open pilot data from
      15 older adults with prospectively demonstrated treatment resistance to venlafaxine who were
      exposed to low-dose BPN, suggesting a clinically meaningful antidepressant effect. In
      addition, since BPN: 1) is available in sublingual formulation and 2) has a favorable safety
      and pharmacokinetic profile, it is an attractive candidate to re-purpose as a molecule for
      LL-TRD. Thus, the overarching aims of this project are to examine the feasibility, safety,
      tolerability and clinical effect of low-dose BPN as a novel treatment for LL-TRD and to
      develop preliminary data about mechanism of action (MOA).

      The overarching aims are to examine the feasibility, safety, and tolerability of
      buprenorphine (BPN) as a novel treatment for late-life treatment resistant depression
      (LL-TRD). This also involves using translational tools of modern neurobiology (fMRI) to
      rapidly obtain proof-of-concept support for further clinical development. Formal dosing
      schedules in the use of buprenorphine have yet to be thoroughly established. This study hopes
      to determine optimal dosing strategies to improve acceptability.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Measure of depression severity, range of 0-60
We calculated the mean change in depression severity for both groups using baseline MADRS and week 8 MADRS scores.
Greater mean change represents better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Symptom Inventory--Anxiety Subscale (BSI)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Measure of Anxiety Theoretical Range 0-2.4 with lower numbers indicating a better outcome.
We calculated the mean change in anxiety for both groups using Phase 1 week 12 time point (baseline) and Phase 2 week 8 time point (final time point).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)</description>
    <arm_group_label>Buprenorphine</arm_group_label>
    <other_name>suboxone</other_name>
    <other_name>buprenex</other_name>
    <other_name>temgesic</other_name>
    <other_name>subutex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matched placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;/= to 50 years.

          2. Major depressive disorder (MDD), single or recurrent, as diagnosed by the Structured
             Clinical Interview for the DSM IV (SCID-IV).

          3. Montgomery-Åsberg Depression Rating Scale (MADRS) &gt;/= to 15.

          4. Has or agrees to establish a clinical relationship with primary care physician (PCP).

          5. Availability of an informant (e.g., emergency contact).

        Exclusion Criteria:

          1. Inability to provide informed consent.

          2. Depressive symptoms not severe enough i.e.,Montgomery-Åsberg Depression Rating Scale (
             MADRS) &lt; 15 at the baseline assessments.

          3. Dementia, as defined by The Modified Mini-Mental State (3MS) examination &lt; 84 and
             clinical evidence of dementia (e.g., memory impairment, executive dysfunction,
             agnosia, apraxia, aphasia, with functional impairment).

          4. Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective
             disorder, schizophreniform disorder, delusional disorder, or current psychotic
             symptoms, as diagnosed by the Structured Clinical Interview for DSM (SCID).

          5. Abuse of or dependence on alcohol or other substances within the past 3 months as
             determined by SCID, and confirmed by study physician interview.

          6. Alcohol use amounting to 15 or more drinks per week or drinking 5 or more drinks on
             one occasion during any given week.

          7. High risk for suicide (e.g., active suicidal ideation (SI) and/or current/recent
             intent or plan) AND unable to be managed safely in the clinical trial (e.g., unwilling
             to be hospitalized). Urgent psychiatric referral will be made in these cases.

          8. Contraindication to venlafaxine extended release (XR) or BPN as determined by study
             physician including history of intolerance of either venlafaxine XR or BPN in the
             study target dosage range (venlafaxine XR at up to 300 mg/day; BPN at up to 2 mg/day).

          9. Inability to communicate in English (i.e., interview cannot be conducted without an
             interpreter; subject largely unable to understand questions and cannot respond in
             English).

         10. Non-correctable clinically significant sensory impairment (i.e., cannot hear well
             enough to cooperate with interview).

         11. Unstable medical illness, including delirium, uncontrolled diabetes mellitus,
             hypertension, or cerebrovascular or cardiovascular risk factors that are not under
             medical management. This will be determined based on information from the patient's
             personal physician and study physician's clinical judgment. Referral to the patient's
             personal physician or to a general practitioner will be made in these cases. Sodium
             and glucose levels done in the past 6 months are also reviewed before a subject begins
             study medication to determine if an illness is stable or uncontrolled. Individual lab
             parameters may deviate from normal without any associated pathophysiology or negative
             clinical affect; therefore we will follow the guide below before beginning starting
             any study medication.

             Sodium value of 135 but asymptomatic= consider to be normal and proceed without
             further testing.

             Sodium value of 134= repeat sodium. If value continues to be at 134 or higher and
             subject is asymptomatic, continue study participation but recheck sodium level after
             one week of exposure to study medication to confirm it has stayed stable.

             Sodium value of 133 or less= will evaluate subject's medication list to suggest
             possibly removing other medications which may be contributing to low sodium (in
             collaboration with their PCP), suggest fluid restriction and require repeat sodium
             that is normal range prior to commencing study.

             Glucose &lt; 275 and asymptomatic= stable to proceed but will communicate value to PCP
             with participants permission.

             (see exclusion #17 for information on hepatic function lab parameters)

         12. Subjects taking psychotropic medications that cannot be safely tapered and
             discontinued prior to study initiation. The following exceptions are allowed if they
             have been taken at a stable dose for at least 4 weeks prior to study entry and there
             is not a plan to change the dose during the next 28 weeks: benzodiazepines up to 2
             mg/d lorazepam equivalent; other sedative-hypnotics (e.g., zolpidem, zaleplon,
             eszopiclone); gabapentin if prescribed for non-psychiatric indication (e.g.,
             neuropathy).

         13. History of opiate abuse or dependence.

         14. Severe pain, defined as &gt;/= 7 on 0-10 numeric rating scale for pain.

         15. Concomitant use of strong or moderate CYP3A4 inhibitor (indinavir, nelfinavir,
             ritonavir, clarithromycin, itraconazole, ketonazole, nefazodone, saquinovir,
             telithromycin, aprepitant, erythromycin, fluconazole, grapefruit juice, verapamil,
             diltiazem)

         16. Refusal to stop all opioids (to avoid precipitating opioid withdrawal).

         17. Hepatic impairment- aspartate aminotransferase (AST) /alanine aminotransferase (ALT) &gt;
             1.5 times upper normal. If AST and ALT are within 1.5 times the upper limit, and
             subjects are asymptomatic, they will be considered medically stable to participate

         18. Estimated Glomerular Filtration Rate (GFR) &lt; 20 ml/min.

         19. Inability/refusal to identify a person as an emergency contact.

         20. Pregnancy

         21. Contraindications to MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordan F. Karp, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Psychiatric Institute and Clinic, University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 25, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <results_first_submitted>April 26, 2018</results_first_submitted>
  <results_first_submitted_qc>May 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2018</results_first_posted>
  <last_update_submitted>August 1, 2018</last_update_submitted>
  <last_update_submitted_qc>August 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Jordan F. Karp</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Buprenorphine</keyword>
  <keyword>Receptors, opioid</keyword>
  <keyword>Receptors, opioid kappa and mu</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT02176291/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT02176291/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Buprenorphine</title>
          <description>Buprenorphine
Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo
Placebo: matched placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Buprenorphine</title>
          <description>Buprenorphine
Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo
Placebo: matched placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="9.7"/>
                    <measurement group_id="B2" value="65.6" spread="7.5"/>
                    <measurement group_id="B3" value="65.0" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Montgomery-Asberg Depression Rating Scale (MADRS)</title>
        <description>Measure of depression severity, range of 0-60
We calculated the mean change in depression severity for both groups using baseline MADRS and week 8 MADRS scores.
Greater mean change represents better outcome.</description>
        <time_frame>baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 1.2 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery-Asberg Depression Rating Scale (MADRS)</title>
          <description>Measure of depression severity, range of 0-60
We calculated the mean change in depression severity for both groups using baseline MADRS and week 8 MADRS scores.
Greater mean change represents better outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in MADRS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.47" spread="8.94"/>
                    <measurement group_id="O2" value="4.09" spread="8.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final MADRS score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.93" spread="8.68"/>
                    <measurement group_id="O2" value="14.64" spread="9.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Symptom Inventory--Anxiety Subscale (BSI)</title>
        <description>Measure of Anxiety Theoretical Range 0-2.4 with lower numbers indicating a better outcome.
We calculated the mean change in anxiety for both groups using Phase 1 week 12 time point (baseline) and Phase 2 week 8 time point (final time point).</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 1.2 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Symptom Inventory--Anxiety Subscale (BSI)</title>
          <description>Measure of Anxiety Theoretical Range 0-2.4 with lower numbers indicating a better outcome.
We calculated the mean change in anxiety for both groups using Phase 1 week 12 time point (baseline) and Phase 2 week 8 time point (final time point).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in BSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="1.39"/>
                    <measurement group_id="O2" value="0.06" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final BSI Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.94"/>
                    <measurement group_id="O2" value="0.64" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over a period of 1 year and six months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Buprenorphine</title>
          <description>Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 1.2 mg/day)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: matched placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>death was determined to be due to cardiac disease unrelated to study participation.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>severe abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>nausea and hypertension</sub_title>
                <description>These two condition were listed as the reasons for hospitalization</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <description>hospitalization for pneumonia</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Blood Pressure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Increased plasma glucose level</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Increased pulse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Falls</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Increased Sleep</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Decreased Libido</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Coughing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Yawning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jordan F. Karp</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-246-6048</phone>
      <email>karpjf@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

